Success Stories: Collaborations With Big Pharma

Collaborations with big biotech and big pharma are on the rise as innovators forge ahead in a challenging economic environment. This growing trend demands creativity and diligent focus on the structure of these agreements to maximize their corporate and product development potential. Panelists will address the following issues and provide case studies that demonstrate how to ensure a successful collaboration:

• Unique arrangement structures at specific product life cycle stages
  
• Protecting IP
  
• Avoiding short-term fallout
  
• The impact of collaboration on future growth and exit strategies
  
• Strategies from both sides of the agreement: increasing the opportunity for future collaborations

パネリスト：

• Richard A. Kaufman, Partner, Foley & Lardner LLP
  
• Richard Bork, Corporate Patent Counsel, Novo Nordisk
  
• Tim Opler, Ph.D., Principal, Torreya Partners
  
• Thomas Beetham, Senior Corporate Counsel, Genzyme
  
• Michael Lytton, Executive Vice President, Corporate and Business Development, Biogen Idec